Obesity Preclinical Contract Research Solutions

Online Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services of Interest *

When do you expect your project to start?

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Advancing Preclinical Obesity Research with the Diet-Induced Obesity (DIO) Mouse Model

Inquiry

Ace Therapeutics is a dedicated preclinical contract research provider focused on obesity research. We specialize in designing and executing scientifically rigorous studies that leverage the Diet-Induced Obesity (DIO) Mouse Model. Our expertise lies in providing innovative preclinical solutions that support the evaluation of potential therapeutic candidates for obesity-related conditions. By combining state-of-the-art methodologies with deep scientific knowledge, we help researchers obtain reliable data to guide early drug discovery and development decisions.

Why Choose the Diet-Induced Obesity (DIO) Mouse Model?

The DIO Mouse Model is a cornerstone in preclinical obesity research due to its ability to recapitulate key features of human metabolic syndrome. This model is particularly valuable for:

Simulating Human Diet-Related Obesity: By inducing obesity through a high-calorie diet, the model closely reflects the lifestyle-related factors that contribute to human obesity, providing a relevant platform for testing therapeutic interventions.
Assessing Metabolic Responses: Researchers can evaluate changes in insulin sensitivity, lipid profiles, and inflammatory markers. This detailed metabolic profiling aids in understanding the mechanisms underlying obesity and its associated complications.
Facilitating Translational Research: Data obtained from studies using the DIO Mouse Model can bridge the gap between basic research and clinical investigation, offering insights that inform subsequent phases of drug development.

Below is a commonly used formulation for a high-fat diet designed to induce obesity in mice:

Ingredient Category	Approximate Percentage (w/w)
High-Fat Source (e.g., lard/oils)	~40%
Protein (e.g., casein)	~20%
Carbohydrates (starches/sugars)	~35%
Other (fiber, vitamins, minerals)	~5%

Comprehensive Preclinical Services Using the DIO Mouse Model

Our end-to-end preclinical solutions are tailored to meet the unique objectives of each study, ensuring alignment with your drug development pipeline.

Customizable Study Designs

We collaborate with clients to define protocols that address specific research questions:

Diet Formulation: High-fat diets with adjustable macronutrient ratios.
Intervention Timing: Prophylactic vs. therapeutic dosing to mimic prevention or treatment scenarios.
Endpoint Selection: Body composition, glucose tolerance tests (GTT), lipid profiling, histopathology, and biomarker analysis.

Metabolic & Physiological Assessments

Beyond weight monitoring, our services include multi-parametric analyses to capture systemic and tissue-level effects:

Energy Homeostasis: Indirect calorimetry, locomotor activity tracking.
Adipose Tissue Analysis: Adipokine profiling, macrophage polarization, gene expression.
Organ-Specific Evaluations: Liver triglyceride quantification, pancreatic β-cell function, cardiac output measurements.

Data-Driven Insights for Decision-Making

Our team delivers interpretable reports with statistical rigor, highlighting:

Dose-dependent responses and therapeutic windows.
Comparative efficacy against reference compounds.
Safety pharmacology endpoints (e.g., off-target effects on renal/hepatic function).

DIO Model Validation Data

Below is a summary of key model validation data for the DIO Mouse Model, outlining observed changes in critical metabolic and physiological parameters that confirm its effectiveness in mimicking obesity phenotypes:

Parameter	Observed Change	Validation Notes
Weight Gain	Increase of 30-40% of baseline body weight	Consistent increase when mice are maintained on a high-fat diet
Adiposity	2-3 fold increase in fat mass	Validated using imaging techniques and post-study dissection
Glucose Tolerance	Impaired compared to control groups	Frequently used to assess metabolic dysfunction in obesity studies
Insulin Sensitivity	Approximately 20-40% reduction	Standard measure indicating decreased insulin sensitivity
Serum Lipid Levels	Elevated cholesterol and triglycerides	Critical for evaluating dyslipidemia as part of metabolic syndrome
Inflammatory Markers	Elevated cytokines (e.g., TNF-α, IL-6)	Indicative of obesity-associated inflammation observed across studies

*Note: Values are representative averages derived from multiple validation studies and may vary based on experimental conditions.

Explore More Models of Obesity and Metabolic Diseases

At Ace Therapeutics, we offer a comprehensive suite of preclinical models to investigate the complex mechanisms underlying obesity and metabolic dysregulation.

ob/ob Mouse Model (Leptin-Deficient Obesity)
Humanized GLP-1R Mouse Model
Zucker Fatty Rat (ZFR) Model
DIO Rat Model (Diet-Induced Metabolic Dysfunction)
MC4R Knockout Mouse (Monogenic Obesity Model)
Streptozotocin-Induced Diabetic Models
Diet-Induced Diabetes Models
Spontaneous Models of Diabetes Mellitus

Applications of the DIO Model in Obesity Drug Development

Our services support diverse therapeutic strategies, including:

Small Molecules: PPARγ agonists, AMPK activators, lipase inhibitors.
Biologics: GLP-1 receptor agonists, adiponectin mimetics.
Natural Products: Phytochemicals with anti-adipogenic properties.
Combination Therapies: Synergistic effects of dual-target agents.

Why Choose Ace Therapeutics?

We tailor our study protocols to align with your specific research goals and experimental needs.
Equipped with advanced imaging and analytical tools, we provide comprehensive and accurate assessments of obesity-related parameters.
Our commitment to strict experimental methodologies and statistical rigor ensures the reliability and reproducibility of your study outcomes.
As your strategic partner, we offer expert consultation and support to optimize your preclinical research endeavors.

Frequently Asked Questions (FAQ) About DIO Mouse Model

What is the Diet-Induced Obesity (DIO) Mouse Model?

The DIO Mouse Model involves inducing obesity in mice by feeding them a high-calorie, high-fat diet. This model simulates several key aspects of human obesity, including weight gain, insulin resistance, and metabolic disturbances, making it a valuable tool for preclinical research.

How does the DIO Mouse Model benefit preclinical obesity research?

This model provides a relevant in vivo platform for evaluating the efficacy and safety of potential therapeutic candidates. It allows researchers to assess metabolic changes, investigate biomarkers, and study the underlying mechanisms of obesity in a controlled environment.

What types of preclinical studies can Ace Therapeutics perform using the DIO Mouse Model?

Our services include designing and executing studies that measure metabolic parameters, evaluate compound effects on obesity-related endpoints, and analyze pharmacodynamic and pharmacokinetic profiles. We customize our approach to meet the specific needs of each research project.

Is your research limited to the DIO Mouse Model?

A: While the DIO Mouse Model is a core component of our obesity research services, we offer a comprehensive suite of preclinical services tailored to various aspects of metabolic research. Our expertise spans multiple experimental approaches designed to support early-stage drug discovery.

How do you ensure the quality and reproducibility of your research findings?

At Ace Therapeutics, we implement rigorous study designs, maintain strict control over experimental conditions, and perform comprehensive data analyses. This methodical approach ensures that our research findings are both reliable and informative for subsequent drug development efforts.